Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viral Kinetics of Telbivudine vs Entecavir in HBeAg-positive CHB
NCT00412529Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2006
- Primary completion
- Feb 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telbivudine in Chronic Hepatitis B (CHB) (2 arms), sponsored by Novartis. Primary endpoint: Change in Mean Hepatitis B Virus (HBV) DNA Levels at 12 weeks. Started Dec 2006; status: completed.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00412529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412529.